Risk assessments clearly document that the number of drugs originating from large pharmaceutical companies which make it to final approval by regulatory authorities is low despite growth in R&D expenditures (Nature Reviews Drug Discovery 7, 197-198). Consequently, translational research, which covers all the steps of transforming scientific discoveries into sustainable health care solutions has gained a lot of importance in the last decade. The National Institutes of Health (NIH) has made translational research a priority, even forming centers of translational research at its institutes. The teaming up of the pharmaceutical industry with small biotech companies adds a new dynamic to the whole process and helps increase success rates in drug development. ADSI as Public Private Partnership with close connections to big international industry partners provides ideal conditions for co-operations, especially in the preclinical stage.